HIMS Stock Recent News

Hims & Hers Health (HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized telehealth options, the business has experienced tremendous growth.

Hims & Hers Health (HIMS -12.33%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas.

The shares of healthcare name Hims & Hers Health Inc (NYSE:HIMS) have retreated from their Feb. 19,  pre-earnings all-time high of $72.98.

The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.

Hims & Hers Health, Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.

HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a tailwind, allowing its core personalized healthcare portfolio to shine, as observed in the double digits non-GLP-1 revenue growth. The same has been observed in the rich FY2024 performance metrics and the management's FY2025 guidance, as they seek to expand their vertically integrated healthcare offerings.

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While bears focus on waning GLP-1 sales, HIMS' business outside GLP-1s is still growing rapidly.

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (HIMS 9.07%) plummeted following its fourth-quarter earnings report. The stock had rocketed from around $24 at the start of the year to over $70 before pulling back.

Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss drugs directly to consumers posted strong growth for the fourth quarter of 2024 but has investors concerned over the legality of its weight loss drug compounds.

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.